Clinical trial · no report yet · Phase 3
OFSET
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- NCT05879926 ↗
- Recruiting
- NRG Oncology
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| YouTube | 9 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression
- Arms
- Arm 1: Ovarian Function Suppression + Aromatase Inhibitor · Active comparator
- Arm 2 Adjuvant Chemotherapy + Ovarian Function Suppression + Aromatase Inhibitor · Active comparator
- Enrollment
- 3,960 (estimated)
- Primary outcomes
- Invasive breast cancer-free survival (IBCFS)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Oct 18, 2023
- Primary completion
- Jan 2032 (estimated)
- Results posted
- No
- Registry record
- NCT05879926 · updated Sep 2, 2026